IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Malagola, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.191
EU - Europa 6.741
AS - Asia 4.729
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 13
SA - Sud America 13
Totale 25.729
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.140
UA - Ucraina 2.315
CN - Cina 2.283
SG - Singapore 1.097
DE - Germania 991
IT - Italia 846
PL - Polonia 798
HK - Hong Kong 717
FI - Finlandia 531
TR - Turchia 405
IE - Irlanda 385
GB - Regno Unito 280
SE - Svezia 259
IN - India 152
FR - Francia 146
CZ - Repubblica Ceca 55
CA - Canada 44
BE - Belgio 41
RU - Federazione Russa 26
VN - Vietnam 23
EU - Europa 20
NL - Olanda 19
MU - Mauritius 14
AU - Australia 13
DK - Danimarca 13
ID - Indonesia 9
JP - Giappone 8
ES - Italia 7
IR - Iran 6
BR - Brasile 5
EG - Egitto 4
GR - Grecia 4
IL - Israele 4
JO - Giordania 4
MY - Malesia 4
BO - Bolivia 3
CO - Colombia 3
CU - Cuba 3
HU - Ungheria 3
PT - Portogallo 3
RO - Romania 3
SA - Arabia Saudita 3
TH - Thailandia 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
CH - Svizzera 2
HR - Croazia 2
KR - Corea 2
LV - Lettonia 2
MX - Messico 2
PK - Pakistan 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CL - Cile 1
EE - Estonia 1
IQ - Iraq 1
JM - Giamaica 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MS - Montserrat 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 25.729
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.001
Jacksonville 1.613
Fairfield 1.565
Houston 1.310
Ann Arbor 1.125
Singapore 865
Ashburn 818
Warsaw 791
Princeton 736
Cambridge 732
Wilmington 728
Hong Kong 716
Chandler 629
Seattle 611
Nanjing 536
Dublin 381
Istanbul 339
Beijing 296
New York 289
Helsinki 238
Nanchang 227
Brescia 196
Des Moines 164
Changsha 125
Jinan 120
Shenyang 119
Hebei 118
Dearborn 110
San Diego 107
Tianjin 102
Shanghai 100
Boardman 85
Jiaxing 84
Milan 81
Hangzhou 69
Kunming 66
Kocaeli 64
Ningbo 54
Brno 50
Regensburg 50
Verona 48
Brussels 41
Pune 40
Zhengzhou 38
London 36
Munich 35
Lanzhou 32
Guangzhou 31
Taizhou 29
San Francisco 28
Haikou 26
Norwalk 26
Orange 26
Toronto 26
Grafing 25
Rome 24
Dong Ket 22
Romola 22
Los Angeles 21
Bologna 14
Taiyuan 13
Barlassina 12
Genoa 12
Hefei 12
Helsingør 12
Kilburn 12
North York 12
Lappeenranta 11
Westminster 11
Darfo 10
Fuzhou 10
Santa Clara 10
Augusta 9
Changchun 9
Hounslow 9
Bosio 8
Jakarta 8
Bergamo 7
Chiswick 7
Gorlago 7
Melbourne 7
Phoenix 7
Porto 7
Redwood City 7
Nürnberg 6
Turin 6
Wroclaw 6
Amsterdam 5
Chicago 5
Crema 5
Falkenstein 5
Florence 5
Leawood 5
New Bedfont 5
São Paulo 5
Tokyo 5
Wandsworth 5
Amman 4
Ardabil 4
Battipaglia 4
Totale 19.309
Salva come PNG Salva come JPEG
Nome #
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 265
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis 263
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 241
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 233
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 223
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 197
Zebrafish disease models in hematology: Highlights on biological and translational impact 173
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 143
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 137
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 133
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 132
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 129
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 127
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 124
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 122
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 122
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 121
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 121
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 121
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 119
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 113
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 113
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. 112
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 112
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 111
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 109
Central nervous system angiitis in Hodgkin's disease. 108
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 107
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 104
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 103
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 103
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 103
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 102
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 102
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia 101
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-kit positive acute myeloid leukemia. Results of an italian multicentric phase II study. 101
Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. 101
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 101
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 100
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 100
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 99
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 99
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 99
Low dose AraC for Myelodysplastic Syndromes: is it still a current therapy ?. 98
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 98
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 98
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 97
Expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation: ongoing results of a prospective study. 96
Conditioning regimens in acute myeloid leukemia. 96
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 96
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 95
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 95
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 95
Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse 94
WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia. 94
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 93
The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era 93
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 92
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. 92
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 92
Changes in Circulating Endothelial Cells Count Could Become a Valuable Tool in the Diagnostic Definition of Acute Graft-Versus-Host Disease. 92
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression 92
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 91
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 91
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 91
Liposomal daunorubicin (DAUNOXOME) for treatment of relapsed meningeal acute myeloid leukemia. 90
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. 89
FLAIE (fludarabine, cytarabine, idarubicin and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: a single center experience. 89
Treatment of Chronic Myeloid Leukemia elderly patients in the Tyrosine Kinase Inhibitor era. 89
AIDA: The italian way of treating acute promyelocytic leukemia (APL): final act . 89
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 88
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 88
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 88
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 88
Four Drugs combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as induction therapy for newly diagnosed acute myeloid leukemia patients younger than 65 yrs: response and follow up of 127 patients. 88
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 86
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 86
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 86
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients 86
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 86
D1CLEARANCE OF HEPATITIS B VIRUS INFECTION IN A PATIENT RECEIVING ALLOGENEIC BONE MARROW TRANSPLANTATION FROM AN HBV NAIVE DONOR. 86
Brentuximab vedotin in patients with hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four italian centers 86
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor 86
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 86
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 86
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 84
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 83
Liposomal daunorubicin (DaunoXome) for the treatment of relapsed meningeal acute myeloid leukemia. 83
Assoication of 3q21 syndrome with different RPN1/EVI1 fusion transcript in AML patients. 83
Chemotherapy of secondary leukemias 82
Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. 82
Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML 82
Advances in CMV Management: A Single Center Real-Life Experience 82
Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. 81
Patterns of Lymphocyte Subsets and Index of Bone Marrow Output (KRECs) Correlate Differently with Graft-Versus-Host Disease and Relapse 81
Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome 81
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. 81
Establishing a New Zebrafish Model to Study Malignant Transformation in Myeloproliferative Disorders. 80
A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING 80
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 80
Totale 10.691
Salva come PNG Salva come JPEG
Categoria #
all - tutte 144.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 144.384
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.205 0 0 0 0 270 655 606 651 450 898 209 466
2020/20214.695 61 482 83 671 139 626 191 625 621 557 459 180
2021/20222.684 121 460 55 130 111 203 128 194 141 365 203 573
2022/20232.153 435 45 53 175 162 597 7 199 259 30 91 100
2023/20242.723 125 72 190 140 130 457 122 93 758 32 40 564
2024/20251.748 62 79 68 775 764 0 0 0 0 0 0 0
Totale 26.694